VS
First Trust NYSE Arca Biotechnology ETF (FBT) and iShares Genomics Immunology and Healthcare Index ETF (XDNA) offer distinct profiles for Canadian ETF investors. A direct comparison shows that FBT focuses its top 3 sector exposures on Healthcare, while XDNA leans towards Healthcare. When evaluating costs, FBT features a management fee (MER) of 0.15%, compared to 0.39% for XDNA. Performance-wise, FBT has returned 33.76% year-to-date with +$4 M in net flows, whereas XDNA is at 60.11% with +$6 M. Use the comparison tool below to benchmark these funds across top 10 holdings, yield, sector weights and historical returns.
NAV Performance and Flows
Key Data
Compare
FBT
XDNA
| AuM | $7.64 M | $16.33 M |
| Management Fees | 0.15% | 0.39% |
| Exp. ratio | 0.71% | 0.44% |
| Tracking Difference | - | -1.01% |
Historical performance and flows
As of September 23, 2026
| 1M | 3M | YTD | 1Y | 3Y | ||
|---|---|---|---|---|---|---|
| Perf. | FBT | +1.92% | +15.81% | +33.76% | +52.73% | +93.79% |
XDNA | +4.79% | +29.62% | +60.11% | +81.37% | +112.40% | |
| Flows | FBT | +$0 M | +$2 M | +$4 M | +$4 M | +$4 M |
XDNA | +$3 M | +$5 M | +$6 M | +$6 M | +$6 M |
FBT vs XDNA exposure
Countries
FBT
USA
82.19%
Other
17.81%
XDNA
USA
60.39%
Germany
8.55%
France
7.33%
Other
23.74%
Sectors
FBT
Healthcare
99.86%
XDNA
Healthcare
99.82%
As of September 23, 2026
Top 10 Holdings
FBT
Halozyme Therapeutics, Inc.
4.31%
Corcept Therapeutics, Inc.
4.08%
Repligen Corp.
3.87%
Regeneron Pharmaceuticals, Inc.
3.85%
BeOne Medicines Ltd.
3.83%
BioNTech SE
3.75%
Natera, Inc.
3.73%
Amgen, Inc.
3.70%
argenx SE
3.66%
NeoGenomics, Inc.
3.63%
XDNA
Bayer AG
4.77%
Twist Bioscience Corp.
4.73%
Revolution Medicines, Inc.
4.61%
Moderna, Inc.
4.37%
Incyte Corp.
4.30%
Takeda Pharmaceutical Co., Ltd.
4.19%
Regeneron Pharmaceuticals, Inc.
4.16%
Genmab A/S
4.12%
Vertex Pharmaceuticals, Inc.
3.86%
Merck & Co., Inc.
3.85%
Diversification
FBT
Total weight of top 10 holdings out of 30 total
38.41%
XDNA
Total weight of top 10 holdings out of 47 total
42.96%
Characteristics
Compare
FBT
XDNA
| Provider | First Trust | iShares |
| Management | Passively managed | Passively managed |
| Benchmark | NYSE Arca Biotechnology Total Return Index - USD | NYSE FactSet Global Genomics and Immuno Biopharma NR Index - CAD |
| Replication Method | Direct (Physical) | |
| Asset Class | Equity | Equity |
| Dividend Policy | Distributing | Distributing |
| Trailing 12m distribution yield | 0.00% | 0.20% |
| Meets ESG criteria | No | No |
| Inception Date | October 30, 2014 | April 26, 2022 |
Frequently asked questions about FBT and XDNA
Which ETF has performed better year to date: FBT or XDNA?
As of September 23, 2026, FBT has returned 33.76% year to date, while XDNA has returned 60.11%. XDNA is ahead on YTD performance.
Which ETF is larger by assets under management: FBT or XDNA?
As of September 23, 2026, FBT manages $7.64 M in assets, while XDNA manages $16.33 M. XDNA is the larger fund by AUM.
How are FBT and XDNA managed?
FBT is passively managed by First Trust. It tracks the NYSE Arca Biotechnology Total Return Index - USD benchmark. XDNA is passively managed by iShares. It tracks the NYSE FactSet Global Genomics and Immuno Biopharma NR Index - CAD benchmark.
What sectors do FBT and XDNA emphasize?
FBT is most exposed to Healthcare. XDNA is most exposed to Healthcare.
Which ETF is attracting more investor flows: FBT or XDNA?
Year to date, FBT has seen +$4.36 M in net flows, compared with +$6.43 M for XDNA. XDNA has attracted more net investor money so far.
How do the fees of FBT and XDNA compare?
FBT has an expense ratio of 0.71%, while XDNA has an expense ratio of 0.44%.
What are the top holdings of FBT and XDNA?
FBT's largest holdings include Halozyme Therapeutics, Inc., Corcept Therapeutics, Inc., and Repligen Corp.. XDNA's top holdings include Bayer AG, Twist Bioscience Corp., and Revolution Medicines, Inc..
Which ETF is more diversified: FBT or XDNA?
FBT holds 30 securities, while XDNA holds 47. On holdings count, XDNA is the more diversified portfolio.
Recent articles about FBT and XDNA
The ETF Market Canada is brought to you by Cboe in partnership with Trackinsight SA who is providing all the data, analysis and editorial content on this site. Unless explicitly stated as such, any information that you receive is not real-time.
All content on the ETF Market Canada is for your general information use only, Cboe is not responsible for any use of content by you outside this scope. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by Cboe and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
All content on the ETF Market Canada is for your general information use only, Cboe is not responsible for any use of content by you outside this scope. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by Cboe and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.